Dr. Weeks’ Comment: I have advocated for deep, restorative sleep and here is another reason. Note that most sleep medications “disrupt sleep architecture” (read it in the package insert). What does it mean to “disrupt sleep architecture”? It means to interfere with normal healthy sleep. Yes; sleeping drugs will make you 1) horizontal, 2) amnestic 3) unresponsive BUT any sleep doc reading your EEG will confirm that you are lacking deep stage 4 restorative sleep when on these medications to the degree they “disrupt sleep architecture”. Ask your sleep doc about “Prozac eyes” which are atypical eye patterns that people taking SSRI medications exhibit in their sleep. So, do sleep medications increase your risk for aggressive breast cancer? Worth reading the package insert yourself!
“Short sleep duration is a public health hazard leading not only to obesity, diabetes and heart disease, but also cancer,”
“Effective intervention to increase duration of sleep and improve quality of sleep could be an under-appreciated avenue for reducing the risk of developing more aggressive breast cancers and recurrence.”
Lack of Sleep Found to Be a New Risk Factor for Aggressive Breast Cancers
ScienceDaily (Aug. 27, 2012) — Lack of sleep is linked to more aggressive breast cancers, according to new findings published in the August issue of Breast Cancer Research and Treatment by physician-scientists from University Hospitals Case Medical Center’s Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University.
Led by Cheryl Thompson, PhD, the study is the first-of-its-kind to show an association between insufficient sleep and biologically more aggressive tumors as well as likelihood of cancer recurrence. The research team analyzed medical records and survey responses from 412 post-menopausal breast cancer patients treated at UH Case Medical Center with Oncotype DX, a widely utilized test to guide treatment in early stage breast cancer by predicting likelihood of recurrence.
All patients were recruited at diagnosis and asked about the average sleep duration in the last two years. Researchers found that women who reported six hours or less of sleep per night on average before breast cancer diagnosis had higher Oncotype DX tumor recurrence scores. The Oncotype DX test assigns a tumor a recurrence score based on the expression level of a combination of 21 genes.
“This is the first study to suggest that women who routinely sleep fewer hours may develop more aggressive breast cancers compared with women who sleep longer hours,” said Dr. Thompson, who is Assistant Professor at Case Western Reserve University School of Medicine and lead author. “We found a strong correlation between fewer hours of sleep per night and worse recurrence scores, specifically in post-menopausal breast cancer patients. This suggests that lack of sufficient sleep may cause more aggressive tumors, but more research will need to be done to verify this finding and understand the causes of this association.”
The authors point out that while the correlation of sleep duration and recurrence score was strong in post-menopausal women, there was no correlation in pre-menopausal women. It is well known that there are different mechanisms underlying pre-menopausal and post-menopausal breast cancers. The data suggest that sleep may affect carcinogenic pathway(s) specifically involved in the development of post-menopausal breast cancer, but not pre-menopausal cancer.
“Short sleep duration is a public health hazard leading not only to obesity, diabetes and heart disease, but also cancer,” said Li Li, MD, PhD, a study co-author and family medicine physician in the Department of Family Medicine at UH Case Medical Center and Associate Professor of Family Medicine, Epidemiology and Biostatistics at Case Western Reserve University School of Medicine. “Effective intervention to increase duration of sleep and improve quality of sleep could be an under-appreciated avenue for reducing the risk of developing more aggressive breast cancers and recurrence.”
The study was supported by National Cancer Institute grants to Case Western Reserve University School of Medicine. Drs. Thompson and Li and other researchers on the study are also associated with the UH Seidman Cancer Center, the Case Comprehensive Cancer Center, the Department of Epidemiology and Biostatistics at Case Western Reserve University, the Center for Clinical Investigation at Case Western Reserve, and the Department of Medicine at UH Case Medical Center and Case Western Reserve University School of Medicine.